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Abstract
Purpose Statins protect against ischemia-reperfusion injury
and limit myocardial infarct size (IS). This effect is dependent
on increased generation of adenosine by ecto-5′ nucleotidase
and downstream activation of cyclooxygenase-2 (COX2).
Dipyridamole (DIP) augments the IS-limiting effects of
statins by blocking the cellular reuptake of adenosine;
whereas aspirin (ASA) attenuates the effect by inhibiting
COX2. We studied the effect of acute administration of DIP,
ASA and their combination on the IS-limiting effect of
simvastatin (SIM).
Methods Rats received oral SIM (10 mg/kg/d) or vehicle
for 3 days. Rats underwent 30 min of coronary artery
occlusion and 4 h reperfusion. After 5 min of ischemia rats
received i.v. DIP (5 mg/kg), ASA (20 mg/kg or 2 mg/kg) or
DIP+ASA (2 mg/kg) or vehicle alone. Ischemia area at risk
(AR) was assessed by blue dye and IS by TTC. Myocardial
samples were analyzed for the activation of Akt, ERK 1/2,
endothelial nitric oxide synthase (eNOS), and cyclic-AMP-
response-element-binding-protein (CREB).
Results SIM limited IS. High- or low-dose ASA alone had
no effect on IS. DIP alone or with low-dose ASA
significantly reduced IS. Low-dose ASA did not attenuate
the SIM effect, whereas high-dose ASA completely
blocked the effect. The combination of DIP+low-dose
ASA+SIM resulted in the smallest IS. Both SIM and
DIP+low-dose ASA augmented Akt phosphorylation and
their effect was additive. Both SIM and DIP+low-dose ASA
augmented eNOS, ERK 1/2 and CREB phosphorylation.
Conclusions During acute myocardial ischemia, DIP alone
or with low-dose ASA limits IS and does not attenuate the
IS-limiting effect of SIM as high-dose ASA.
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Introduction
Dipyridamole (DIP) increases interstitial adenosine concen-
trations by blocking the cellular reuptake of adenosine [1,
2]. When administered intravenously at high doses (ie,
0.56 mg/kg over 4 min), DIP may exacerbate myocardial
ischemia by diverting blood flow from diseased vessels
with fixed narrowings to healthier branches undergoing
vasodilatation [3]. However, when administered orally at
low doses (ie, 300–400 mg/d), DIP has significant
antiplatelet effects and causes minimal hemodynamic
changes. In the clinical setting, DIP has been used to
prevent cardiovascular and cerebrovascular events [2].
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DOI 10.1007/s10557-010-6252-xRecently, the Prevention Regimen for Effectively Avoiding
Second Strokes (PRoFESS) study compared the effects of
low-dose aspirin (ASA), combined with extended-release
DIP (25 mg and 200 mg, respectively; twice daily), with the
effects of clopidogrel (75 mg/d) on the secondary preven-
tion of stroke [4]. In both treatment groups, the rates of
recurrent stroke and of the combined endpoint—stroke,
myocardial infarction (MI), and vascular death—were
similar [4]. However, in patients with acute MI, the role
of DIP (alone or in combination with low-dose ASA) is less
clear.
When given to patients with stable angina or acute
coronary syndromes, intracoronary DIP before percutane-
ous transluminal coronary angioplasty was reported to
reduce the risk of abrupt vessel closure [5, 6]. Furthermore,
intracoronary DIP reduced the incidence of adverse
cardiovascular events in the first 48 h after balloon
angioplasty of small coronary arteries [7]. Yoshida and
colleagues [8] also reported that intracoronary DIP admin-
istered for acute anterior wall MI before primary percuta-
neous coronary intervention prevented reperfusion
arrhythmia. However, in a study by Thompson and
colleagues [9], 202 patients with ST-segment elevation
myocardial infarction (STEMI) who were randomly
assigned to receive either a continuous intravenous heparin
infusion or oral DIP (100 mg, 3 times a day) and ASA
(300 mg/d) 24 h after thrombolytic therapy had similar
outcomes. Seven to 10 days after treatment, no differences
were observed in clinical events or the rates of patency of
the infarct-related artery [9].
The American College of Cardiology (ACC)/American
Heart Association (AHA) guidelines for the management of
patients with STEMI do not recommend the use of DIP as
an antiplatelet agent. According to these guidelines, the
combination of low-dose ASA and extended-release DIP is
reserved for STEMI patients who have ischemic stroke but
do not undergo percutaneous coronary intervention and do
not have a cardiac source of embolism or a surgically
important carotid stenosis [10–12]. The possibility that DIP
could cause coronary steal and augment ischemia in the
setting of acute MI may be the reason for these guidelines.
Numerous studies have shown that the hydroxymethyl
glutaryl coenzyme A reductase inhibitors (statins) reduce
myocardial infarct size [13–18]. The use of statins for
patients at high risk for cardiovascular events and for those
presenting with acute myocardial infarction is recommen-
ded by the guidelines. Previously, we showed that when
given orally, DIP augmented the effects of atorvastatin by
further reducing the myocardial infarct size (IS) in rats [13].
Statins activate ecto-5′-nucleotidase, which generates aden-
osine [14]. Inhibition of adenosine receptors not only
abrogates the IS-limiting effect of statins [13, 14], but
prevents statins from inducing the phosphorylation of the
prosurvival mediators ERK 1/2, Akt, and endothelial nitric
oxide synthase (eNOS) [15]. The protective, IS-limiting
effects of statins are also dependent on the activation of
cyclooxygenase-2 (COX2) [16, 17], which can be attenuated
by ASA, a nonspecific cyclooxygenase inhibitor, in a dose-
dependent manner [18].
In our study, we investigated the effects of high- or low-
dose ASA and DIP on infarct size, when given alone or in
combination with simvastatin (SIM), a hydroxymethyl
glutaryl coenzyme A reductase inhibitor (statin), during
myocardial ischemia in rats.
Materials and methods
Animal care
Experiments were performed in male Sprague-Dawley rats.
All animals received humane care in compliance with the
Guide for the Care and Use of Laboratory Animals
published by the United State National Institutes of Health
(NIH Publication No. 85-23, revised 1996).
Materials
DIP was provided by Boehringer Ingelheim GmbH (Ger-
many). ASA was obtained from Sigma (St. Louis, MO) and
SIM from Merck (Whitehouse Station, NJ). Anti-Akt, anti-
Thr308 P-Akt, and anti-Ser-473 P-Akt antibodies were
obtained from R&D Systems (Minneapolis, MN). Anti-
eNOS, anti-Ser-1177 P-eNOS, anti-ERK 1/2, anti-Thr-202/
Tyr-204 P-ERK 1/2, anti-CREB, and anti-Ser-133 P-CREB
antibodies were purchased from Cell Signaling Technology,
Inc. (Beverly, MA). Monoclonal anti-β-actin antibodies
were obtained from Sigma.
Treatment
Rats received either simvastatin (10 mg/kg/d) or vehicle
(water) by means of oral gavage once daily for 3 days. On
the fourth day, the rats were anesthetized with an
intraperitoneal injection of ketamine (60 mg/kg) and
xylazine (6 mg/kg) and were intubated and ventilated
(FIO2=30%). The rectal temperature of the rats was
monitored, and their body temperature was maintained
between 36.7° and 37.3°C throughout the experiment. After
the left carotid artery was cannulated, the chest was opened
through the fourth intercostal space. The left coronary
artery was encircled with a suture and ligated for 30 min.
Five minutes after the start of ischemia, 1 of the following
agents was infused intravenously for 120 min: vehicle
(control); high-dose ASA (20 mg/kg, ASA20); low-dose
ASA (2 mg/kg, ASA2); DIP alone (5 mg/kg); or a
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titrated to effect) was given to the rats after the start of
ischemia to maintain anesthesia. After 30 min of ischemia,
the snare was released and myocardial reperfusion was
verified by a change in the color of the myocardium.
Subcutaneous buprenorphine (0.1 mg/kg) was adminis-
tered, the chest was closed. At the end of the infusion
(25 min during myocardial ischemia and the first 95 min of
reperfusion), the rats were allowed to recover from
anesthesia at the end of the infusion. Four hours after
reperfusion (IS protocol) and 95 min after reperfusion
(immunobloting), the rats were re-anesthetized, and the
coronary artery was reoccluded; 1.5 ml of Evans blue dye
(3%) was injected into the right ventricle, and the rats were
euthanized while under deep anesthesia [13, 16, 17]. The
heart rate (HR) and mean blood pressure (MBP) were
recorded immediately before coronary artery occlusion,
after 20 min of ischemia, and after 20 min of reperfusion.
The prespecified exclusion criteria included a lack of
signs of ischemia during coronary artery ligation, lack of
signs of reperfusion after release of the snare, prolonged
ventricular arrhythmia with hypotension, and an area at risk
measuring ≤10% of the left ventricular (LV) weight.
Determination of area at risk and infarct size
The rat hearts were excised, and the left ventricle was sliced
transversely into 6 sections. The slices were incubated for
10 min at 37°C in 1% buffered (pH=7.4) 2,3,5-triphenyl-
tetrazolium-chloride (TTC), and were fixed in a 10%
formaldehyde solution. The sections were photographed to
identify the ischemic area at risk (AR)(not colored by the
blue dye), the infarct size (IS)(unstained by TTC), and the
nonischemic zones (colored by blue dye). In each slice,
the AR and IS were determined by means of planimetry,
converted into percentages of the whole for each slice, and
multiplied by the weight of the slice. The results were
summed to obtain the weight of the myocardial AR and IS
[13, 16, 17].
Immunoblotting
Rats in the control group were treated with water, by means
of oral gavage for 3 days, and were not subjected to the
ischemia-reperfusion protocol. The other groups were
treated as above and exposed to 30 min of ischemia and
95 min of reperfusion. There were 4 animals in each group.
Myocardial samples from the border of the previously
identified ischemic AR zone of the LV wall of treated rats
and myocardial samples of control rats were homogenized
in lysis buffer (25 mmol Tris-HCl [pH=7.4], 0.5 mmol
EDTA, 0.5 mmol EGTA, 1 mmol phenylmethylsulfonyl
fluoride, 1 mmol dithiothreitol, 25 mmol NaF, 1 mmol
Na3VO4, 1% Triton X-100, 2% sodium dodecyl sulfate
[SDS], and 1% protease inhibitor cocktail). The lysate was
centrifuged at 10,000 × g for 15 min at 4°C, and the
supernatants were collected. Protein (50 μg) was fraction-
ated by SDS polyacrylamide gel electrophoresis (PAGE;
4%–20%) and transferred to polyvinylidene fluoride mem-
branes (Millipore, Bedford, MA), which were incubated
overnight at 4°C with primary antibodies. Bound antibodies
were detected by using a chemiluminescent substrate (NEN
Life Science Products, Boston, MA). The protein signals
were quantified with an image-scanning densitometer, and
the strength of each protein signal was normalized to the
corresponding β-actin signal. The data are expressed as a
percentage of the expression in the control group.
Statistical analysis
Unless otherwise noted, the data are presented as the mean ±
standard error of the mean. Body weight, left ventricular
weight, the size of the area at risk and infarct size, and protein
expression were compared by using analysis of variance
(ANOVA) with Sidak corrections for multiple comparisons.
The differences in HR and MBP were compared by using
two-way repeated-measures (treatment × time) ANOVAwith
Holm-Sidak multiple comparison procedures. P<0.05 was
considered statistically significant.
Results
IS protocol
A hundred rats began the protocol, 4 rats died during the
induction of anesthesia (1 in the SIM group, 1 in the ASA20
group, 1 in the SIM+ASA20, and 1 in the ASA2+DIP
group) and 2 during surgery (1 in the ASA20 and 1 in the
SIM+ASA20 group). A total of 94 rats were included.
Body weight, left ventricular weight, and area at risk
sizes were comparable among groups (Table 1). The IS,
expressed as a percentage of the left ventricular weight
(Table 1) or as a percentage of the AR (Table 1; Fig. 1), was
significantly smaller in the SIM, ASA2+DIP, DIP, SIM+
ASA2, and SIM+ASA2+DIP groups than in the control
group. The IS in the ASA2, ASA20, and SIM+ASA20
groups was not significantly different from that in the
control group (Table 1; Fig. 1). Both the 3-day pretreatment
with SIM alone and the intravenous administration of DIP
during occlusion reduced the IS. However, low- or high-
dose ASA alone (2 mg/kg or 20 mg/kg, respectively)
administered during occlusion had no effect on IS. In rats
pretreated with SIM, however, high-dose ASA blocked the
protective IS-limiting effect of SIM. Low-dose ASA did not
attenuate the effects of SIM or DIP. The SIM+ASA2+DIP
Cardiovasc Drugs Ther (2010) 24:391–399 393group showed the smallest IS (Fig. 1), although the
differences between the IS of this group and the IS of the
SIM+ASA2 or the SIM-alone groups did not reach
statistical significance. The difference between the IS of
the SIM+ASA2+DIP and ASA2+DIP groups was of
borderline significance (P=0.061; Fig. 1).
The HR was unaffected by the different treatments (P=
0.062). Although significant changes in HR were observed
in all rats from the time of preocclusion to 20 min after
reperfusion (P<0.001), the interaction between treatment
and time was not significant (P=0.166; Fig. 2a). The MBP
significantly decreased from the time of preocclusion to
20 min after reperfusion (P<0.001; Fig. 2b), but the
difference among the control and treatment groups was
not significant (P=0.062). However, with respect to MBP,
the interaction between treatment and time was significant
(P=0.001). During coronary occlusion, the MBP was
significantly lower in the SIM+ASA2+DIP group (98.6±
9.4 mmHg) than in the control group (112.0±0.3 mmHg),
the DIP-alone group (111.7±2.4 mmHg), and the SIM
+ASA2 group (115.5±2.2 mmHg) but not in the ASA2
+DIP group (106.4±2.3 mmHg). In addition, during
coronary occlusion, the MBP was significantly higher in
the SIM+ASA2 group (115.5±2.2 mmHg) than in the SIM
+ASA20 group (104.4±0.9 mmHg) but not in the ASA20-
only group (108.0±2.3 mmHg). These differences are not
consistent with any of the drugs’ known effects and were
most likely random. No other significant changes were
detected from baseline (preocclusion) to the time of
reperfusion.
Immunoblotting
There were 4 animals in each group. The total Akt and total
eNOS protein levels were comparable among the treatment
and control groups (Fig. 3). Ischemia-reperfusion alone
increased myocardial levels of Ser-473 P-Akt and Thr-308
P-Akt compared to controls not subjected to ischemia-
reperfusion (Fig. 3). SIM and ASA2+DIP increased Ser-
473 P-Akt and Thr-308 P-Akt levels, whereas ASA20 had
no significant effect. For the SIM+ASA20 group, ASA20
did not block the SIM-induced increase in P-Akt levels
(Fig. 3), despite blocking the IS-limiting effects of SIM
(Fig. 1). The highest levels of Ser-473 P-Akt and Thr-308
P-Akt were seen in the SIM+ASA2+DIP group (Fig. 3).
Ischemia-reperfusion alone caused a mild increase in
Ser-1177 P-eNOS levels (Fig. 3). SIM and ASA2+DIP
increased P-eNOS levels. ASA20 had no significant effect
on P-eNOS levels, and in the SIM+ASA20 group, ASA20
did not block the effect of SIM. No significant differences
Table 1 Body weight, left ventricular weight, area at risk, and infarct size of control and treated rats
Treatment group BW (g) LV weight (mg) Area at risk
(% of LV weight)
Infarct size
(% of LV weight)
Infarct size
(% of area at risk)
Control (n=10) 259±5 1105±7 29.3±0.8 13.5±1.1 45.7±2.9
SIM (n=11) 259±2 1110±2 30.9±1.1 6.4±0.3 21.0±1.5
ASA2 (n=10) 257±3 1110±4 28.4±0.7 10.9±1.1 38.4±3.5
ASA20 (n=10) 258±3 1112±4 28.5±0.8 11.6±0.9 40.3±2.7
ASA2+DIP (n=10) 259±3 1115±4 27.4±0.8 6.5±0.5 23.6±1.7
DIP (n=10) 258±2 1116±3 29.0±0.9 7.1±0.4 24.6±0.9
SIM+ASA2 (n=13) 259±2 1114±4 27.2±0.9 5.4±0.3 20.0±1.2
SIM+ASA20 (n=10) 259±1 1115±3 28.2±0.7 12.4±0.5 44.2±2.1
SIM+ASA2+DIP(n=10) 259±1 1115±4 28.1±0.8 3.8±0.3 13.8±1.5
P value 0.999 0.570 0.138 <0.001 <0.001
BW body weight; LV left ventricular; SIM simvastatin; DIP dipyridamole; ASA aspirin
Fig. 1 Myocardial infarct size (IS) shown as a percentage of the area
at risk (AR) in control and treatment groups. Data are presented as the
mean ± standard error of the mean. Overall, a significant difference
was observed in infarct size among different treatment groups (P<
0.001). * P<0.001 versus control; # P<0.001 versus DIP+ASA2
+SIM; $ P=0.061 versus DIP+ASA2+SIM
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SIM+ASA20, ASA2+DIP, and SIM+ASA2+DIP groups
(Fig. 3).
As shown in Fig. 4, the protein levels of total ERK 1/2
or cyclic AMP response element binding protein (CREB)
were comparable among the treatment and control groups.
Ischemia-reperfusion alone increased myocardial levels of
P-ERK 1/2. ASA20 had no significant effect, whereas SIM
alone or with ASA20 augmented myocardial levels of P-
ERK 1/2. DIP+ASA2 increased P-ERK 1/2 levels more than
did SIM (P= 0 . 0 0 6 )o rS I M + A S A 2 0( P=0.024). P-ERK 1/2
levels were significantly higher in the DIP+ASA2+SIM
group than those in all other groups, except the DIP+ASA2
group (P=0.916).
Ischemia-reperfusion alone increased P-CREB levels
(Fig. 4). ASA20 did not alter the effect of ischemia-
reperfusion on P-CREB. However, SIM, SIM+ASA20,
DIP+ASA2, and DIP+ASA2+SIM increased myocardial
levels of P-CREB equally (Fig. 4).
Discussion
In our study, we showed that the intravenous infusion of
DIP (5 mg/kg over 2 h), started during myocardial ischemia
and continued during the first 95 min of reperfusion,
significantly reduced IS to an extent comparable with 3-day
SIM pretreatment, without causing significant hemodynam-
ic changes. Furthermore, when the intravenous infusion of
DIP and low-dose ASA was combined with SIM pretreat-
ment, the IS was reduced to an even greater extent than
with SIM or DIP alone. Low-dose ASA did not affect the
IS-limiting effects of SIM, but high-dose ASA completely
blocked the IS-limiting effects of SIM.
Previously, we have shown that pretreating rats with
orally administered DIP (6 mg/kg/d) and low-dose atorvas-
tatin (2 mg/kg/d) limited IS in a synergistic manner [13].
When administered alone, however, neither low-dose
atorvastatin nor DIP affected the infarct size. Low-dose
atorvastatin and DIP each caused a small increase in
myocardial adenosine levels, although when these agents
were combined, adenosine levels were significantly in-
creased. Furthermore, only the combination of low-dose
atorvastatin and DIP increased myocardial Ser-473 P-Akt
and Ser-1177 P-eNOS levels [13]. Aminophylline, a
nonselective adenosine receptor blocker, abrogated the IS-
limiting effect of DIP and atorvastatin, suggesting that the
protective effects of both drugs are mediated by the
activation of adenosine receptors.
In our experiments, we used a rate of infusion of DIP
(0.042 mg/kg/min) significantly lower than the rate used to
induce ischemia during pharmacologic stress tests
(0.14 mg/kg/min); however, we used an absolute dose that
is much higher (5 mg/kg versus 0.56 mg/kg) [3]. DIP
blocks the cellular reuptake of adenosine, thus increasing
interstitial adenosine levels [1, 2]. DIP causes vasodilation
of blood vessels and has antiplatelet effects [1, 2]. In
addition, Harker and Kadatz have suggested that DIP is a
cAMP phosphodiesterase inhibitor and that it increases the
biosynthesis of prostacyclin (PGI2)[ 1].
The IS-limiting effects of statins are dependent on the
activation of ecto-5-nucleotidase, which generates adeno-
sine and phosphatidylinositol-3-kinase that promotes the
phosphorylation of the pro-survival kinase Akt [14]. The
inhibition of adenosine receptors abrogates the IS-limiting
Fig. 2 Heart rate (HR, shown in beats per minute) and mean blood
pressure (MBP, shown in mmHg) from pre-occlusion to 20 min after
the start of reperfusion. a The different treatments did not significantly
affect HR (P=0.062). HR changed significantly over time (P<0.001),
but the interaction between treatment and time was not statistically
significant (P=0.166). b MBP significantly decreased over time (P<
0.001). Overall, no significant differences were observed in MBP
among the treatment groups (P=0.062), although there was a
significant interaction between treatment and time (P=0.001)
Cardiovasc Drugs Ther (2010) 24:391–399 395effects of statins [13, 14] and prevents statins from inducing
the phosphorylation of the prosurvival mediators Erk 1/2,
Akt, and eNOS [15]. We have previously shown that the
adenosine receptors A1,A 2A, and A2B are involved in the
statin-induced activation of Akt and eNOS [15]. Activation
of the adenosine receptors A2A and A2B leads to an increase
in intracellular cAMP and the subsequent activation of
protein kinase A (PKA), in addition to the activation of
other prosurvival kinases, including ERK 1/2 [19]. Both
PKA [20, 21] and its downstream effector, phosphorylated
CREB (P-CREB) [22, 23], are involved in myocardial
protection against ischemia-reperfusion-related injury.
In our study, SIM and DIP+ASA2 increased myocardial
levels of P-CREB. A major nuclear transcription factor,
CREB transduces signals from cAMP to activate gene
transcription [24]. CREB is activated by phosphorylation at
Ser-133 by PKA [24, 25], which can also be mediated by
Akt [24, 26], the MEK/MAPK/p90rsk pathway [27], Ca
2+/
calmodulin-dependent protein kinase II [27], protein kinase
Cε [28], protein kinase D [29], ERK 1/2, and mitogen and
stress-activated protein kinase-1 (MSK-1) [22]. CREB
phosphorylation induces the translocation of CREB from
the cytoplasm to the nucleus where it regulates the
transcription of target genes [24]. CREB also binds a
cAMP-response element site in the promoter region of
genes such as cytochrome C and Bcl-xl, which CREB has
been shown to positively regulate [30]. CREB is involved
in ischemic preconditioning [22, 23].
Interestingly, despite the fact that ASA20 blocked the
IS-limiting effect of SIM, it did not attenuate the
phosphorylation of CREB, suggesting that COX2 func-
tions downstream of CREB activation. Moreover, despite
a smaller IS in the DIP+ASA2+SIM group, comparable
myocardial levels of P-CREB were observed in the SIM,
SIM+ASA20, and DIP+ASA2 groups, suggesting that
other signaling pathways are involved in limiting IS.
In addition to activating the cAMP, PKA, and CREB
pathways, SIM and DIP+ASA2 activated 2 prosurvival
kinases–Akt and ERK 1/2— that are known to mediate
protection against ischemia-reperfusion and reperfusion
injury [31, 32]. Although high-dose ASA attenuated the
IS-limiting effect of SIM, it did not block the effect of SIM
β−actin
T-eNOS
Ser-1177 P-eNOS 
T-Akt
Thr-308 P-Akt
Ser-473 P-Akt 
C
o
n
t
r
o
l
C
o
n
t
r
o
l
A
S
A
2
0
S
I
M
S
I
M
+
A
S
A
2
0
D
I
P
+
A
S
A
2
D
I
P
+
A
S
A
2
+
S
I
M
Ischemia-reperfusion
Fig. 3 Representative immunoblots and densitometric analyses of Ser-
473 P-Akt, Thr-308 P-Akt, total Akt, Ser-1177 P-eNOS, and total
eNOS in the border zone of hearts exposed to the ischemia-reprefusion
protocol. The myocardium of rats that were not exposed to ischemia-
reperfusion and received vehicle served as the control. β-actin was used
as a loading control. * P<0.001 versus ischemia-reperfusion control;
# P<0.001 versus DIP+ASA2+SIM
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because Akt and ERK 1/2 activation are upstream of COX2
activation [15]. The effects of DIP+ASA2 and SIM on the
phosphorylation of Akt were additive when all 3 treatments
were combined; this finding paralleled the effect of these
agents on myocardial IS. However, it is interesting that
DIP+ASA2 increased P-ERK 1/2 levels more than did SIM
or SIM+ASA20 (Fig. 4) and that the effect of DIP+ASA2
on ERK 1/2 phosphorylation was comparable to that of
SIM+DIP+ASA2, suggesting that there was no additive
effect.
As previously described, pretreatment with statins
augmented eNOS phosphorylation [13, 14, 17]. eNOS
activation is essential for mediating the protective effects
of statins, and it is upstream of COX2 activation [33]. In the
present study we are showing that DIP+low-dose ASA
infusion during ischemia and early reperfusion had equal
effect on eNOS phosphorylation as 3-day pretreatment with
SIM. However, the combination of SIM with DIP+ASA2
did not result in additive effect on eNOS phosphorylation in
myocardium subjected to ischemia-reperfusion. As expected,
high-dose ASA did not block the effect of pretreatment with
SIM, as COX2 is downstream of eNOS activation [33].
COX2 activation is essential for the IS-limiting effects of
statins [17, 18]. We have previously shown that ASA dose
dependently (5, 10 and 20 mg/kg) attenuated COX2 activity
and that COX2 activity inversely correlated with IS [18].
We have also shown that COX2 inhibition abrogates the IS
limiting effects of atorvastatin without affecting the
upregulation of eNOS phosphorylation and iNOS expres-
sion by atorvastatin [17].
We found that ASA20, but not ASA2 attenuated the IS
limiting effects of SIM. In the clinical setting, it is
recommended that patients with acute ST elevation myocar-
dial infarction will receive chewed aspirin at 160–325 mg/kg
[18]. In Europe an intravenous dose of 250–500 mg is often
used. For a 70 kg patient this represents up to 7.1 mg/kg.
Doses of medications given to rats and mice are usually
much higher than those used in the clinical setting. We have
previously shown that intravenous aspirin (10 and 20 mg/
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Fig. 4 Representative immunoblots and densitometric analyses of
total ERK 1/2, Thr 202/ Tyr-204 P-ERK 1/2, total CREB, and Ser-133
P-CREB in the border zone of hearts exposed to ischemia-reperfusion.
The myocardium of rats that were not exposed to ischemia-reperfusion
and received vehicle served as the control. β-actin was used as a
loading control. * P<0.001 versus ischemia-reperfusion control; # P<
0.001 versus DIP+ASA2+SIM
Cardiovasc Drugs Ther (2010) 24:391–399 397kg), administered before reperfusion, attenuates the infarct
size limiting effects of atorvastatin [18]. At 5 mg/kg there is
attenuation, but it does not reach statistical significance [18].
Further studies are needed to assess whether such adverse
interaction occurs in the clinical setting.
Limitations: in the present study we did not assess the
effect of DIP alone without low-dose ASA on the
expression of the prosurvival kinases; however, ASA2 did
not attenuate the IS-limiting effects of DIP (Fig. 1).
Furthermore, we have previously shown that the inhibitory
effect of ASA on the IS-limiting effects of atorvastatin is
dose dependent and is only minimal at 5 mg/kg [18]. ASA
alone, even at the higher dose, does not affect myocardial
IS [18]. The results of our two studies are comparable,
showing that at 2 mg/kg, ASA does not attenuate the
protective effect of SIM (Fig. 1).
In our model, myocardial infarction is induced in rats by
mechanically compressing the artery, rather than by causing
the spontaneous formation of a blood clot on a ruptured
coronary plaque. In the clinical setting, the inhibition of
platelet activity has a significant role in the treatment of
acute myocardial infarction [10, 11]. Although DIP+ASA2
have antiplatelet properties, their effects should be com-
pared to those of ASA combined with thienopyridines,
which are currently the first-choice agents for inhibiting
platelet aggregation per ACC/AHA guidelines. Therefore,
studies are warranted that would compare the effects of
high-dose ASA with thienopyridine versus low-dose
ASA+DIP+thienopyridine; or alternatively, low-dose
ASA+DIP versus thienopyridine with ASA in patients
receiving statin agents.
In conclusion, when started after coronary artery occlusion
and continued during early reperfusion, intravenous infusion
ofDIP+ASA2appearedtobesafeandwasnotassociatedwith
significant hemodynamic changes. Furthermore, DIP+ASA2
was associated with a significant reduction in the myocardial
ISandwithactivationoftheprosurvivalkinasesAktandERK
1/2, CREB, and eNOS. Thus, the combination of DIP and
low-dose ASA should be considered as an alternative to the
higher dose ASA currently used, especially in patients
receiving statins. Further studies are needed to verify if such
interactions occur in the clinical setting.
Open Access This article is distributed under the terms of the
Creative Commons Attribution Noncommercial License which per-
mits any noncommercial use, distribution, and reproduction in any
medium, provided the original author(s) and source are credited.
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